Odile Launay, MD, PhD

Université de Paris, Inserm F-CRIN I-REIVAC

Disclosure: AstraZeneca (Grant/Research Support)GlaxoSmithKline (Consultant, Grant/Research Support, Other Financial or Material Support, Data safety monitoring board)Johnson & Johnson (Consultant, Grant/Research Support)Moderna (Consultant)Pfizer (Consultant, Grant/Research Support)Sanofi Pasteur (Consultant, Grant/Research Support)

Presentation(s):

• LB5 - PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults

  Thursday, September 30, 2021
  6:15 PM – 6:30 PM EDT